Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 6,620,000 shares, an increase of 43.6% from the March 15th total of 4,610,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the days-to-cover ratio is presently 3.1 days. Currently, 8.2% of the company's shares are sold short.
Compass Therapeutics Price Performance
Shares of Compass Therapeutics stock traded up $0.14 during trading on Wednesday, hitting $2.12. 721,641 shares of the company's stock traded hands, compared to its average volume of 865,749. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08. The business has a 50-day simple moving average of $2.30 and a 200-day simple moving average of $2.09. The stock has a market capitalization of $293.16 million, a P/E ratio of -5.73 and a beta of 1.40.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, equities analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.
Insider Transactions at Compass Therapeutics
In related news, insider Jonathan Anderman acquired 20,000 shares of Compass Therapeutics stock in a transaction on Monday, April 7th. The shares were acquired at an average cost of $1.54 per share, with a total value of $30,800.00. Following the transaction, the insider now owns 21,000 shares in the company, valued at $32,340. This trade represents a 2,000.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. Corporate insiders own 28.50% of the company's stock.
Institutional Trading of Compass Therapeutics
Several large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its position in Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after purchasing an additional 12,917 shares during the last quarter. Independent Advisor Alliance purchased a new stake in Compass Therapeutics during the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets bought a new position in Compass Therapeutics in the fourth quarter worth approximately $27,000. XTX Topco Ltd purchased a new position in shares of Compass Therapeutics during the 3rd quarter worth $37,000. Finally, Mariner LLC bought a new stake in shares of Compass Therapeutics during the 4th quarter valued at $30,000. Institutional investors own 68.43% of the company's stock.
Analyst Ratings Changes
CMPX has been the subject of a number of research analyst reports. Piper Sandler started coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 target price for the company. Guggenheim restated a "buy" rating on shares of Compass Therapeutics in a report on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $24.00 price target on shares of Compass Therapeutics in a research note on Monday. Leerink Partners upgraded shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $4.00 to $6.00 in a report on Wednesday, April 2nd. Finally, Leerink Partnrs upgraded shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 1st. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Compass Therapeutics has an average rating of "Buy" and a consensus target price of $13.38.
View Our Latest Stock Report on CMPX
Compass Therapeutics Company Profile
(
Get Free Report)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
See Also
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
